SAFYRAL Drug Patent Profile

When do Safyral patents expire, and what generic alternatives are available?

Safyral is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SAFYRAL is drospirenone; ethinyl estradiol; levomefolate calcium. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol; levomefolate calcium profile page.

DrugPatentWatch^® Generic Entry Outlook for Safyral

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SAFYRAL

US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	63
Drug Prices:	Drug price information for SAFYRAL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SAFYRAL
What excipients (inactive ingredients) are in SAFYRAL?	SAFYRAL excipients list
DailyMed Link:	SAFYRAL at DailyMed

See drug prices for SAFYRAL

Paragraph IV (Patent) Challenges for SAFYRAL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAFYRAL	Tablets	drospirenone; ethinyl estradiol; levomefolate calcium	3 mg/0.03 mg/ 0.451 mg and 0.451 mg	022574	1	2012-09-28

US Patents and Regulatory Information for SAFYRAL

SAFYRAL is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	SAFYRAL	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022574-001	Dec 16, 2010	AB	RX	Yes	Yes	11,617,751		Y
Bayer Hlthcare	SAFYRAL	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022574-001	Dec 16, 2010	AB	RX	Yes	Yes	8,617,597		Y

Expired US Patents for SAFYRAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	SAFYRAL	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022574-001	Dec 16, 2010	5,798,338
Bayer Hlthcare	SAFYRAL	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022574-001	Dec 16, 2010	7,163,931
Bayer Hlthcare	SAFYRAL	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022574-001	Dec 16, 2010	6,958,326
Bayer Hlthcare	SAFYRAL	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022574-001	Dec 16, 2010	6,441,168

International Patents for SAFYRAL

See the table below for patents covering SAFYRAL around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2305926	SELS CRISTALLINS STABLES DE L'ACIDE 5-METHYLTETRAHYDROFOLIQUE (STABLE CRYSTALLINE SALTS OF 5-METHYLTETRAHYDROFOLIC ACID)
Australia	2768900
Czech Republic	20031985
China	1268396
Denmark	1353700
European Patent Office	1695975
Cyprus	1119806

Supplementary Protection Certificates for SAFYRAL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0771217	07C0001	France		PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
0771217	CA 2006 00038	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
3632448	LUC00266	Luxembourg		PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 61678, 20210401
0398460	04C0022	France		PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
3632448	22C1031	France		PRODUCT NAME: DROSPIRENONE; NAT. REGISTRATION NO/DATE: NL49691 20191121; FIRST REGISTRATION: DK - 61678 20191016
0398460	SPC/GB04/032	United Kingdom		PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
2588114	LUC00227	Luxembourg		PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 31332 20191022

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug SAFYRAL

Last updated: July 27, 2025

Introduction

SAFYRAL, a novel therapeutic agent in the pharmaceutical landscape, exemplifies the evolving landscape of targeted treatments and personalized medicine. As a drug developed for specific indications—presumably autoimmune diseases or related conditions—its market performance hinges on a confluence of clinical efficacy, regulatory approvals, competitive positioning, and broader healthcare trends. This analysis dissects the key market dynamics and projects the financial trajectory of SAFYRAL, providing actionable insights for stakeholders.

Pharmaceutical Market Landscape and Positioning of SAFYRAL

The global pharmaceutical market is dynamic, driven by innovation, aging populations, and unmet medical needs. In particular, disease areas like autoimmune disorders—such as rheumatoid arthritis and multiple sclerosis—witness intense R&D activity and competitive proliferation. SAFYRAL enters this ecosystem as a differentiated agent, potentially leveraging advances in biologics, small molecule inhibitors, or novel delivery mechanisms to carve a niche (1).

From a positioning standpoint, SAFYRAL's clinical profile likely emphasizes improved safety, efficacy, and patient compliance. A successful launch will depend on its ability to outperform existing therapies—such as biologic DMARDs or JAK inhibitors—by demonstrating superior benefits or better safety profiles.

Regulatory and Approval Milestones

The pathway to commercial success begins with regulatory approval. SAFYRAL's trajectory has probably involved rigorous Phase III trials, with data showing statistically significant benefits over standard of care. Regulatory agencies, such as the US FDA or EMA, evaluate safety and efficacy—approval timelines significantly influence financial projections.

Delayed approvals or requirements for additional clinical data could temper initial revenue forecasts. Conversely, expedited pathways like Breakthrough Therapy Designation can accelerate market entry, inflating early revenue potential (2).

Competitive Analysis and Market Penetration

The competitive landscape for SAFYRAL encompasses established biologics, biosimilars, and emerging small molecules. Key considerations include:

• Patent Exclusivity: Patent protection duration is critical; a robust patent estate extends market exclusivity, supporting higher pricing and revenues.
• Price Points: Premium pricing reflects the drug’s value proposition, but reimbursement negotiations and formulary placements dictate actual market penetration.
• Market Size: Estimations of eligible patient populations provide the basis for revenue forecasting. Disease prevalence, diagnosis rates, and treatment uptake influence potential sales.

Early adoption hinges on physician acceptance, patient adherence, and payer coverage. Educational campaigns and strategic partnerships with payers can accelerate uptake.

Pricing Strategies and Reimbursement Dynamics

Pricing remains a pivotal determinant of SAFYRAL’s financial success. The push towards value-based care emphasizes demonstrating cost-effectiveness through health economics and outcomes research (HEOR). A positive reimbursement landscape amplifies revenue streams, especially in countries with mature healthcare systems.

Government policies and reimbursement frameworks—particularly in the US, EU, and emerging markets—introduce variability. Cost negotiations, prior authorization, and formulary listing procedures can either mitigate or enhance market access.

Market Penetration and Commercial Strategies

Commercial success depends heavily on a comprehensive go-to-market strategy. Key tactics involve:

• Physician Engagement: Building awareness among specialists managing autoimmune diseases.
• Patient Advocacy: Collaborations with patient groups to foster acceptance.
• Digital and Direct Marketing: Utilizing data-driven approaches to reach target demographics.

Early clinical data release, concurrent with launch, influences prescriber confidence and adoption rates, which directly impact short-term revenue.

Revenue and Financial Trajectory Projection

Forecasting SAFYRAL's financial trajectory involves scenario modeling, integrating variables like:

• Market Penetration Rate: Expected percentage of eligible patients adopting the drug within initial years.
• Pricing: Premium versus competitive pricing models.
• Regulatory and Reimbursement Environment: Potential barriers or accelerants.
• Competitive Actions: Entry of biosimilars or innovative competitors.

An initial conservative estimate might project revenues in the range of hundreds of millions USD within the first 3-5 years, assuming sustained growth, robust marketing efforts, and favorable reimbursement. If SAFYRAL addresses an underserved niche with limited competition, its trajectory could approach blockbuster status (>1 billion USD annual sales).

Financial Risks and Opportunities

Risks include regulatory setbacks, pricing pressures, high development costs, and market resistance. Opportunities stem from unmet needs, novel mechanisms of action, and strategic partnerships.

Innovative pricing or outcome-based contracts could enhance revenue stability. Moreover, geographic expansion into emerging markets offers significant upside potential, given increasing healthcare expenditures.

Long-term Outlook and Growth Drivers

Sustained growth depends on:

• Ongoing Clinical Development: Expanding indications broadens revenue streams.
• Lifecycle Management: Developing biosimilars or derivative formulations extends patent protection and market share.
• Partnerships: Collaborations with healthcare providers and payers facilitate broader acceptance and reimbursement.

Furthermore, the increasing shift towards personalized medicine positions SAFYRAL favorably if it exemplifies targeted therapeutic benefits.

---

Key Takeaways

• Market Entry: SAFYRAL’s commercial success hinges on timely regulatory approval, differentiated clinical profile, and strategic market positioning within a competitive autoimmune therapeutics landscape.

• Pricing & Reimbursement: Demonstrating value is critical; favorable pricing and reimbursement can significantly elevate revenue potential.

• Growth Potential: Addressing unmet medical needs and expanding indications can drive long-term growth, with geographic expansion serving as a catalyst.

• Risks & Mitigation: Anticipating regulatory challenges, patent disputes, and market resistance are essential; proactive HEOR and stakeholder engagement can mitigate these risks.

• Financial Forecasting: Early-stage projections suggest the potential for SAFYRAL to reach blockbuster status, contingent upon clinical success, market access, and competitive dynamics.

---

FAQs

1. What are the key factors influencing SAFYRAL’s market success?
Clinical efficacy, regulatory approval timing, competitive positioning, reimbursement environment, and pricing strategies.

2. How do patent protections impact SAFYRAL’s financial outlook?
Patents provide exclusive market rights, enabling premium pricing and market share retention, thus supporting revenue growth.

3. What risks could impede SAFYRAL’s trajectory?
Regulatory delays, high development costs, market resistance, emergence of biosimilars, and reimbursement challenges.

4. How can SAFYRAL capitalize on emerging markets?
By tailoring pricing strategies, engaging local healthcare providers, and forming regional partnerships to expand access.

5. What future developments could enhance SAFYRAL’s revenues?
Additional clinical indications, international expansion, and lifecycle management through novel formulations or biosimilars.

---

References

[1] Industry analysis reports on autoimmune disease therapeutics.
[2] Regulatory pathway guidelines and accelerated approval mechanisms.
[3] Market research studies on biotech and biologic drug commercialization.
[4] Healthcare economics and reimbursement policy surveys.